Efimosfermin alfa, a long-acting FGF21 analogue, showed a favorable safety and tolerability profile in adults with phenotypic MASH.
Up to 100% of participants in higher-dose cohorts achieved at least a 30% reduction in hepatic fat fraction after 12 weeks, compared to 7% in the placebo group.
Gastrointestinal adverse events were the most common side effects, but were mild to moderate and resolved spontaneously.
